| Title |
Driver Mutations in Melanoma: Lessons Learned From Bench-to-Bedside Studies
|
|---|---|
| Published in |
Current Oncology Reports, June 2012
|
| DOI | 10.1007/s11912-012-0249-5 |
| Pubmed ID | |
| Authors |
Janice M. Mehnert, Harriet M. Kluger |
| Abstract |
The identification of somatic driver mutations in human samples has allowed for the development of a molecular classification for melanoma. Recent breakthroughs in the treatment of metastatic melanoma have arisen as a result of these significant new insights into the molecular biology of the disease, particularly the development of inhibitors of activating BRAF(V600E) mutations. In this article the roles of several mutations known to be involved in the malignant transformation of melanocytes are reviewed including BRAF, PTEN, NRAS, ckit, and p16 as well as some of the emerging mutations in cutaneous and uveal melanoma. The bench to bedside collaborations that resulted in these discoveries are summarized, and potential therapeutic strategies to target driver mutations in specific patient subsets are discussed. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 89 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Japan | 1 | 1% |
| Switzerland | 1 | 1% |
| Unknown | 87 | 98% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 19 | 21% |
| Student > Bachelor | 12 | 13% |
| Researcher | 10 | 11% |
| Student > Master | 10 | 11% |
| Other | 6 | 7% |
| Other | 13 | 15% |
| Unknown | 19 | 21% |
| Readers by discipline | Count | As % |
|---|---|---|
| Agricultural and Biological Sciences | 24 | 27% |
| Biochemistry, Genetics and Molecular Biology | 20 | 22% |
| Medicine and Dentistry | 12 | 13% |
| Immunology and Microbiology | 3 | 3% |
| Pharmacology, Toxicology and Pharmaceutical Science | 2 | 2% |
| Other | 8 | 9% |
| Unknown | 20 | 22% |
Attention Score in Context
This research output has an Altmetric Attention Score of 4. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 18 December 2017.
All research outputs
#6,920,783
of 22,694,633 outputs
Outputs from Current Oncology Reports
#276
of 874 outputs
Outputs of similar age
#49,284
of 164,348 outputs
Outputs of similar age from Current Oncology Reports
#3
of 5 outputs
Altmetric has tracked 22,694,633 research outputs across all sources so far. This one has received more attention than most of these and is in the 68th percentile.
So far Altmetric has tracked 874 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 5.8. This one has gotten more attention than average, scoring higher than 67% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 164,348 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 68% of its contemporaries.
We're also able to compare this research output to 5 others from the same source and published within six weeks on either side of this one. This one has scored higher than 2 of them.